Overview of Projects
Clinical and Translational Research Accelerator (CTRA) currently has many projects under way. Below you will find information regarding each of them. If you are interested in learning more about them, you can explore their individual pages or contact us.
Acute Interstitial NephritisClinical diagnosis of acute interstitial nephritis (AIN) is challenging as there are no reliable non-invasive biomarkers and its diagnosis currently requires a kidney biopsy.
Kidney Precision Medicine Program at Yale AKI SiteIn the hopes of discovering therapeutic targets for acute kidney injury, which currently has no specific therapy, the NIH/NIDDK has created the Kidney Precision Medicine Program consortium.
Phenotyping Deceased Donor Acute Kidney Injury to Predict Recipient Outcomes (Ancillary Study Using DDS)There are over 100,000 patients awaiting a kidney transplant, but only 20% will receive one.
The Role of Adaptive and Maladaptive Repair Biomarkers in Predicting Cardiac and Renal Outcomes after an Episode of AKI (Ancillary Study using ASSESS-AKI)
Acute kidney injury (AKI) is a risk factor for chronic kidney disease (CKD) and cardiovascular disease (CVD) with several biological processes orchestrating either recovery or progression to poor long-term outcomes after the initial insult
Chronic Kidney Disease in ChildrenProgression of chronic kidney disease (CKD) in children leads to end stage kidney disease (ESKD), which is associated with mortality rates 30-150 times higher than the general pediatric population.
Acute Kidney Injury in Marathon RunnersParticipation in marathons has gained popularity in the United States with up to 1100 marathons and 507, 600 finishers.
Electronic Alerts for Acute Kidney Injury Amelioration (ELAIA-1)Acute kidney injury (AKI) affects up to 20% of hospitalized patients and increases the risk of dying in the hospital by a factor of 10.
Drug Targeted Alerts for Acute Kidney Injury Amelioration (ELAIA-2)This trial will randomize patients with acute kidney injury (AKI) who are receiving a kidney-toxic medication to alerts (highlighting the particular medication) versus usual care.
Learning Alerts for Acute Kidney Injury (ELAIA-3)This trial will use an advanced machine-learning technique known as uplift modeling to target AKI alerts to a subset of patients who are most likely to be benefited by reducing alert fatigue and improving overall effectiveness.
Predicting Imminent AKI (AKI Tomorrow)While AKI carries substantial risk, there remains no therapeutic intervention that can alter the course of AKI once it develops, beyond optimizing usual care.
Targeting Histone Deacetylase in Focal Segmental Glomerulosclerosis: From Mice to PatientsOur prior research in a mouse model of proteinuric kidney disease revealed upregulation of a protein called histone deacetylase (HDAC).
Risk EValuation And its Impact on ClinicAL Decision Making and Outcomes in Heart Failure: The REVeAL-HF TrialAcute heart failure is the most common cause of hospitalizations in the United States with an associated mortality that exceeds most cancers.
Rheumatology Translational Research Laboratory BiorepositoryThe Rheumatology Translational Research Laboratory Biorepository was created to support translational research geared towards understanding the pathophysiology of rheumatic, connective tissue and autoimmune diseases
The Kidney BiobankThe Kidney Biobank was created by the Yale Section of Nephrology to support translational research focused on understanding the pathophysiology and therapies of kidney diseases.
DOM-CovXThe Department of Medicine COVID Explorer (DOM-CovX) is a tool aimed at democratization of clinical data for the purpose of furthering clinical research and hypothesis generation.
The PROMPT TrialsThe Pragmatic Trial Of Messaging to Providers (PROMPT) Trials are pragmatic, randomized trials focused on improving patient care through the provision of electronic medical record-based alerts.
Kidney Action TeamAcute kidney injury (AKI) is common in the hospital setting, occurring in up to 5-20% of hospitalized adults.